Amit Panwalkar

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

Corey J. Langer, Shirish M. Gadgeel, Hossein Borghaei et al. · The Lancet Oncology · 2016 · 1.4K citations

Oncology, Metronomic Therapy, Pathology +7

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 568 citations · Full text

Medicine, Immunology, Pathology +5

Hormone Replacement Therapy Is Associated With Decreased Survival in Women With Lung Cancer

Apar Kishor Ganti, Abe E. Sahmoun, Amit Panwalkar et al. · Journal of Clinical Oncology · 2005 · 200 citations · Full text

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

Hossein Borghaei, Corey J. Langer, Shirish M. Gadgeel et al. · Journal of Thoracic Oncology · 2018 · 194 citations

24-Month Overall Survival, First-line Therapy, Oncology +7

Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC

Mark M. Awad, Shirish M. Gadgeel, Hossein Borghaei et al. · Journal of Thoracic Oncology · 2020 · 175 citations

Advanced Nonsquamous Nsclc, Medicine, Without Pembrolizumab +7